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An aim of the presentation will be to review the relative
importance of ARV penetration into the central nervous
system (CNS) for optimizing virological response and
minimizing cognitive deficits. A brief summary of clini-
cal studies addressing the importance of ARV penetra-
tion will be included. A focus of the discussion will be
on pharmacological factors driving CNS penetration
(e.g. protein binding, lipophilicity and interaction with
membrane transporters). The talk will summarize cur-
rent knowledge for the most widely prescribed ARVs.
Methodological approaches will be discussed in that stu-
dies addressing CNS penetration often rely on sparse
PK measurements within the cerebrospinal fluid (CSF)
coupled with population PK modelling. Few studies
include intensive pharmacokinetic (PK) measurements
in both CSF and plasma for estimating the CSF/plasma
exposure ratio. Pharmacodynamic studies assessing the
importance of CSF PK exposure for virological response
will be reviewed with an emphasis on the newer ARVs
including raltegravir. Raltegravir achieves CSF concen-
trations providing adequate HIV inhibition in the major-
ity of patients. Results for additional new ARVs will also
be presented.
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